Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer J Catalan-Figueroa, S Palma-Florez, G Alvarez, HF Fritz, MO Jara, ... Nanomedicine 11 (2), 171-187, 2016 | 37 | 2016 |
Nanoparticles as potential novel therapies for urinary tract infections SV Sánchez, N Navarro, J Catalán-Figueroa, JO Morales Frontiers in cellular and infection microbiology 11, 656496, 2021 | 35 | 2021 |
Early IGF-1 gene therapy prevented oxidative stress and cognitive deficits induced by traumatic brain injury AJ Montivero, MS Ghersi, ... Frontiers in Pharmacology 12, 2021 | 32 | 2021 |
Finding key nanoprecipitation variables for achieving uniform polymeric nanoparticles using neurofuzzy logic technology MO Jara, J Catalan-Figueroa, M Landin, JO Morales Drug delivery and translational research 8, 1797-1806, 2018 | 30 | 2018 |
Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study L Gaete, I Saavedra, I Moreno, L Quiñones, J Catalán, C Miranda, Á Roco, ... Biomedica 32 (4), 570-577, 2012 | 25 | 2012 |
Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival CA Acevedo, LA Quiñones, J Catalán, DD Cáceres, JA Fullá, AM Roco Urologic Oncology: Seminars and Original Investigations 32 (3), 280-290, 2014 | 18 | 2014 |
A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers L Quiñones, J Sasso, E Tamayo, J Catalán, JP González, M Escala, ... Therapeutic Advances in Chronic Disease 1 (4), 141-148, 2010 | 15 | 2010 |
A mechanistic approach for the optimization of loperamide loaded nanocarriers characterization: Diafiltration and mathematical modeling advantages J Catalan-Figueroa, CB Boisset, MO Jara, ME Flores, I Moreno-Villoslada, ... European Journal of Pharmaceutical Sciences 125, 215-222, 2018 | 13 | 2018 |
A clinical perspective: anti tau's treatment in Alzheimer's disease P Fuentes, J Catalan Current Alzheimer Research 8 (6), 686-688, 2011 | 13 | 2011 |
Poloxamer 188-coated ammonium methacrylate copolymer nanocarriers enhance loperamide permeability across Pgp-expressing epithelia J Catalan-Figueroa, MA García, P Contreras, CB Boisset, PM Gonzalez, ... Molecular Pharmaceutics 18 (2), 743-750, 2020 | 9 | 2020 |
Metabolismo de los antipsicóticos: enzimas y genes relacionados J Catalán, J Garay, F Romero, CE Miranda Melo, AM Roco Arriagada, ... Sociedad de Farmacología de Chile, 2011 | 7 | 2011 |
Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements SS Gaikwad, JO Morales, NB Lande, J Catalán-Figueroa, UD Laddha, ... International journal of pharmaceutics, 124169, 2024 | 5 | 2024 |
Lithium: Molecular interactions, clinical actions JF Catalán, MP Quezada Translational Neuroscience 3, 61-66, 2012 | 2 | 2012 |
Beyond Acute Traumatic Brain Injury: Molecular Implications of Associated Neuroinflammation in Higher-Order Cognitive Processes AJ Montivero, MS Ghersi, J Catalán-Figueroa, ML Formica, N Camacho, ... Psychiatry and Neuroscience Update: From Epistemology to Clinical Psychiatry …, 2021 | 1 | 2021 |
Safety and nanotoxicity aspects of nanomedicines for brain-targeted drug delivery J Catalan-Figueroa, JO Morales Nanomedicines for Brain Drug Delivery, 255-277, 2020 | 1 | 2020 |
Desarrollo de nanovehículos cubiertos de poloxámero como estrategia para mejorar la solubilidad y permeabilidad de loperamida como modelos de fármaco liposoluble y sustrato de … JF Catalán Figueroa Universidad de Chile, 2019 | | 2019 |
Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study I Moreno, L Quiñones, J Catalán, C Miranda, Á Roco, J Sasso, E Tamayo, ... Biomedica 32 (4), 570-577, 2012 | | 2012 |
Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: A pilot study Influencia de polimorfismos genéticos de cyp3a4/5 en la farmacocinética de … I Moreno, L Quiñones, J Catalán, C Miranda, Á Roco, J Sasso, ... | | 2012 |